Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
3.
An. bras. dermatol ; 93(2): 299-301, Mar.-Apr. 2018. graf
Artículo en Inglés | LILACS | ID: biblio-1038267

RESUMEN

Abstract: Diphencyprone has been reported as a local immunotherapy for cutaneous melanoma metastases. We aim to report cases of melanoma patients treated with diphencyprone in a single Brazilian institution and highlight their outcomes. Since 2012, we have treated 16 melanoma patients with cutaneous metastases with topical diphencyprone. To date, we have had 37.5% of complete response, 25% of partial responses, and 31.25% patients without any response. Treatment was well tolerated and local toxicity was easily controlled. We believe topical diphencyprone is a feasible treatment that can be another option for treating melanoma patients, especially in cases of in-transit or extensive disease.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , Neoplasias Cutáneas/tratamiento farmacológico , Ciclopropanos/uso terapéutico , Melanoma/tratamiento farmacológico , Melanoma/secundario , Antineoplásicos/uso terapéutico , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/secundario , Biopsia , Administración Cutánea , Brasil , Resultado del Tratamiento , Melanoma/patología
5.
Braz. j. med. biol. res ; 49(6): e4806, 2016. tab, graf
Artículo en Inglés | LILACS | ID: biblio-951682

RESUMEN

New generation antidepressant therapies, including serotonin-norepinephrine reuptake inhibitor (SNRIs), were introduced in the late 1980s; however, few comprehensive studies have compared the benefits and risks of various contemporary treatments for major depressive disorder (MDD) in young patients. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science, and PsycINFO databases was conducted from 1970 to January 2015. Only clinical trials that randomly assigned one SNRI or placebo to patients aged 7 to 18 years who met the diagnostic criteria for major depressive disorder were included. Treatment success, dropout rate, and suicidal ideation/attempt outcomes were measured. Primary efficacy was determined by pooling the risk ratios (RRs) of treatment response and remission. Acceptability was determined by pooling the RRs of dropouts for all reasons and for adverse effects as well as suicide-risk outcomes. Five trials with a total of 973 patients were included. SNRIs were not significantly more effective than placebo for treatment response but were for remission. The comparison of patients taking SNRIs that dropped out for all reasons and those taking placebo did not reach statistical significance. Significantly more patients taking SNRIs dropped out for adverse effects than those taking placebo. No significant difference was found in suicide-related risk outcomes. SNRI therapy does not display a superior efficacy and is not better tolerated compared to placebo in these young patients. However, duloxetine has a potential beneficial effect for depression in young populations, showing a need for further research.


Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Ensayos Clínicos Controlados Aleatorios como Asunto , Trastorno Depresivo Mayor/tratamiento farmacológico , Inhibidores de Captación de Serotonina y Norepinefrina/uso terapéutico , Antidepresivos/uso terapéutico , Placebos/uso terapéutico , Ciclopropanos/uso terapéutico , Succinato de Desvenlafaxina/uso terapéutico , Clorhidrato de Duloxetina/uso terapéutico , Milnaciprán
6.
Yonsei Medical Journal ; : 928-935, 2016.
Artículo en Inglés | WPRIM | ID: wpr-63330

RESUMEN

PURPOSE: Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV1) <50% predicted] with chronic bronchitis and a history of frequent exacerbations. This study evaluated the efficacy and safety of roflumilast in Korean patients with COPD and compared the efficacy based on the severity of airflow limitation. MATERIALS AND METHODS: A post-hoc subgroup analysis was performed in Korean COPD patients participating in JADE, a 12-week, double-blinded, placebo-controlled, parallel-group, phase III trial in Asia. The primary efficacy endpoint was the mean [least-squares mean adjusted for covariates (LSMean)] change in post-bronchodilator FEV1 from baseline to each post-randomization visit. Safety endpoints included adverse events (AEs) and changes in laboratory values, vital signs, and electrocardiograms. RESULTS: A total of 260 Korean COPD patients were recruited, of which 207 were randomized to roflumilast (n=102) or placebo (n=105) treatment. After 12 weeks, LSMean post-bronchodilator FEV1 increased by 43 mL for patients receiving roflumilast and decreased by 60 mL for those taking placebo. Adverse events were more common in the roflumilast group than in the placebo group; however, the types and frequency of AEs were comparable to those reported in previous studies. CONCLUSION: Roflumilast significantly improved lung function with a tolerable safety profile in Korean COPD patients irrespective of the severity of airflow limitation.


Asunto(s)
Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Aminopiridinas/uso terapéutico , Pueblo Asiatico , Benzamidas/uso terapéutico , Ciclopropanos/uso terapéutico , Método Doble Ciego , Inhibidores de Fosfodiesterasa 4/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , República de Corea , Pruebas de Función Respiratoria , Resultado del Tratamiento
10.
Rev. chil. dermatol ; 22(1): 18-23, 2006. ilus, tab, graf
Artículo en Español | LILACS | ID: lil-433894

RESUMEN

Estudio retrospectivo de pacientes atendidos con diagnóstico de Alopecia Areata en el Servicio de Dermatología del Centro de Diagnóstico de la Pontificia Universidad Católica de Chile. Se revisaron las fichas de 77 pacientes con diagnóstico de Alopecia Areata, 38 por ciento hombres, 62 por ciento mujeres, con un promedio de edad de 26.7 (DSI 15.7; rango 2-65): 15 por ciento presentaron depresión, 11 por ciento rinitis alérgica, 6,5 por ciento presentaron ansiedad, 3,9 por ciento hipotiroidismo y 2,6 por ciento, vitíligo. La Alopecia Areata se asocia a un evento estresante en 27 por ciento de los pacientes. Dentro de los exámenes solicitados, un 2/26 tuvieron anticuerpos antitiroídeos positivos y 2/27, TSH alterada. Se discuten las diversas modalidades terapéuticas para tratar la Alopecia Areata.


Asunto(s)
Masculino , Adolescente , Adulto , Humanos , Femenino , Preescolar , Niño , Persona de Mediana Edad , Alopecia Areata/complicaciones , Alopecia Areata/etiología , Alopecia Areata/tratamiento farmacológico , Ciclopropanos/uso terapéutico , Corticoesteroides/uso terapéutico , Quimioterapia Combinada , Enfermedades de la Piel/complicaciones , Enfermedades de la Tiroides/complicaciones , Inmunoterapia , Acontecimientos que Cambian la Vida , Minoxidil/uso terapéutico , Estudios Retrospectivos , Trastornos Mentales/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA